About usOur team
Our science
Our pipeline
News
Investors
Contact us
About usOur team
Our science
Our pipeline
News
Investors
Contact us

News

ASX Releases

March 17, 2023

RAD to Present at Virtual Healthcare Conference

Read moreRead more
March 3, 2023

Dr Kenn Herrmann appointed to RAD Scientific Advisory Board

Read moreRead more
March 3, 2023

RAD to acquire Pharma15 Corporation

Read moreRead more
February 14, 2023

RAD Initiates Process for Nasdaq Listing

Read moreRead more
January 11, 2023

Dr. Rama Abu Shmeis appointed Senior VP, CMC

Read moreRead more
December 29, 2022

avB6 Integrin (RAD301) IND Approval for Phase 1 Trial

Read moreRead more

MEDIA releases

May 2, 2023

Positive new publication for RAD301 platform

Read moreRead more
February 21, 2023

FNN Interview with CEO about RAD's ambition to list on Nasdaq

Read moreRead more
February 16, 2023

Investor Webinar

Read moreRead more
February 14, 2023

RAD CEO interview with Proactive Investors and announcement of Nasdaq listing initiation

Read moreRead more
December 1, 2022

GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients

Read moreRead more
October 6, 2022

CEO Interview series with Wholesale Investor

Read moreRead more

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.
About usOur teamRadiopharmaceuticals
Our technologyAbstracts & publicationsOur pipeline
NewsInvestorsPrivacy Policy
Contact us+61 3 9824 5254info@radiopharmtheranostics.com
© Copyright 2023 | All Rights Reserved
Site by Charles Lloyd